Overview

MOTS-c is a 16-amino-acid peptide encoded within a small open reading frame in the mitochondrial 12S ribosomal RNA gene. Its identification by Pinchas Cohen’s group at USC in 2015 was one of a small number of mitochondrial-derived peptides (MDPs) now recognised as retrograde signalling molecules between the mitochondrion and nucleus. Research on MOTS-c has focused on its role in metabolic homeostasis, exercise adaptation, and biological ageing.

Mechanism (as reported in the literature)

  • AMP-activated protein kinase (AMPK) activation. Studies indicate MOTS-c activates AMPK, phenocopying calorie-restriction and exercise-signalling patterns in skeletal muscle and other tissues.
  • Folate cycle interaction. Research characterises MOTS-c as modulating the folate-methionine cycle and one-carbon metabolism, contributing to its effects on insulin sensitivity in reported animal-model work.
  • Retrograde nuclear signalling. Studies report MOTS-c translocation into the nucleus under metabolic stress, where it interacts with stress-response transcription factors.
  • Exercise-response amplification. Animal studies indicate MOTS-c administration mimics some of the metabolic adaptations to endurance training.

Research findings

  • Metabolic-homeostasis animal studies. Studies in high-fat-diet mice report improvements in insulin sensitivity, glucose disposal, and reduced hepatic steatosis with MOTS-c administration (Lee et al., 2015; PMID 25738459).
  • Exercise-capacity studies. Aged-mouse studies report increased treadmill endurance and improved skeletal-muscle metabolic parameters after MOTS-c administration (Reynolds et al., 2021, Nature Communications).
  • Human observational work. Circulating MOTS-c levels have been reported to decline with age and to correlate with insulin sensitivity across observational cohorts.

Common dosing (from published research protocols)

Animal studies most commonly report intraperitoneal doses of 0.5–5 mg/kg. Community research writeups describe subcutaneous doses of 5–10 mg per administration, two or three times weekly.

Reconstitution

A 10 mg vial reconstituted with 2 mL of bacteriostatic water yields a 5,000 mcg/mL solution.

  • 5,000 mcg = 1.00 mL = 100 units on a U-100 syringe
  • 10,000 mcg = 2.00 mL — the full vial

Storage

Reconstituted MOTS-c is refrigerated at 2–8 °C and reported as stable for approximately 30 days.

  • Epithalon — a distinct longevity-associated peptide.
  • NAD+ — a small-molecule cofactor commonly discussed in the same longevity research context.

Common stacks

References

  • Lee, C., et al. (2015). “The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance.” Cell Metabolism, 21(3). PMID 25738459.
  • Reynolds, J. C., et al. (2021). “MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis.” Nature Communications, 12(1). PMID 33436608.
  • Kim, S. J., et al. (2018). “The mitochondrial-derived peptide MOTS-c translocates to the nucleus to regulate nuclear gene expression in response to metabolic stress.” Cell Metabolism, 28(3). PMID 30057067.